Halozyme Therapeutics
HALO
NASDAQ
IPO2004
about HALO
Halozyme Therapeutics develops enzyme-based solutions for improving drug delivery, particularly through its lead product, a recombinant hyaluronidase used to enhance the absorption of subcutaneous medications.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $66.80 | $66.99 | $65.56 | $7.74B | 1.34M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$1.36 | 16.74 | 25.71 | 62.15% | 50.71% | 0% |